Journal
NATURE MEDICINE
Volume 16, Issue 7, Pages 809-U112Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.2154
Keywords
-
Funding
- Wellcome Trust
- European Union
- RISET
- Medical Research Council UK
- Garfield Weston Trust
- Becton Dickinson
- Swedish Heart and Lung Foundation
- Swedish Research Council
- Medical Research Council [G0800842] Funding Source: researchfish
- MRC [G0800842] Funding Source: UKRI
Ask authors/readers for more resources
Transplant arteriosclerosis is the hallmark of chronic allograft dysfunction (CAD) affecting transplanted organs in the long term(1,2). These fibroproliferative lesions lead to neointimal thickening of arteries in all transplanted allografts(2). Luminal narrowing then leads to graft ischemia and organ demise. To date, there are no known tolerance induction strategies that prevent transplant arteriosclerosis(3,4). Therefore, we designed this study to test the hypothesis that human regulatory T cells (T-reg cells) expanded ex vivo can prevent transplant arteriosclerosis. Here we show the comparative capacity of T-reg cells, sorted via two separate strategies, to prevent transplant arteriosclerosis in a clinically relevant chimeric humanized mouse system. We found that the in vivo development of transplant arteriosclerosis in human arteries was prevented by treatment of ex vivo-expanded human T-reg cells. Additionally, we show that T-reg cells sorted on the basis of low expression of CD127 provide a more potent therapy to conventional T-reg cells. Our results demonstrate that human T-reg cells can inhibit transplant arteriosclerosis by impairing effector function and graft infiltration. We anticipate our findings to serve as a foundation for the clinical development of therapeutics targeting transplant arteriosclerosis in both allograft transplantation and other immune-mediated causes of vasculopathy(5).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available